Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG1FQW)

• Drug Name: IDRA-21 Drug Info
• Synonyms: IDRA-21 analogs; IDRA-5

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 3688
  ChEBI ID: CHEBI:111162
  CAS Number: CAS 22503-72-6
  TTD Drug ID: DMG1FQW

Molecule-Related Drug Atlas

Drug(s) Targeting Glutamate receptor AMPA (GRIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[3]
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[4]
Zopiclone	DMPI6Z0	Insomnia	7A00-7A0Z	Approved	[5]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[6]
Enflurane	DM0YJSB	Anaesthesia	9A78.6	Approved	[7]
Isoflurane	DMY6T31	Anaesthesia	9A78.6	Approved	[8]
Bromazepam	DMY9TCW	Anxiety disorder	6B00-6B0Z	Approved	[9]
Artemisinin SP	DMFETDK	Malaria	1F40-1F45	Approved	[10]
Dihydroergotoxine	DM5D6WZ	Alzheimer disease	8A20	Approved	[11]
Barbiturate	DMJIA6T	Anaesthesia	9A78.6	Approved	[12]

Drug(s) Targeting N-methyl-D-aspartate receptor (NMDAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Glutamic Acid	DM4PUDW	Schizophrenia	6A20	Approved	[13]
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[14]
Benzphetamine	DMIJATC	Obesity	5B81	Approved	[15]
Ketamine	DMT5HA4	Anaesthesia	9A78.6	Approved	[16]
Felbamate	DM1V5ZS	Epilepsy	8A60-8A68	Approved	[17]
Memantine	DMD9WSC	Alzheimer disease	8A20	Approved	[18]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[19]
Levorphanol	DMGS80V	Pain	MG30-MG3Z	Approved	[20]
Magnesium Sulfate	DMVEK07	Acute pain	MG31	Approved	[21]
Magnesium	DMU4ORS	Ischemic stroke	8B11.5Z	Approved	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate receptor AMPA (GRIA)	TTAN6JD	NOUNIPROTAC	Modulator	[2]
N-methyl-D-aspartate receptor (NMDAR)	TT9IK2Z	NOUNIPROTAC	Modulator	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4219).
• [2] IDRA-21, a positive AMPA receptor modulator, inhibits synaptic and extrasynaptic NMDA receptor mediated events in cultured cerebellar granule cells. Neuropharmacology. 2004 Jun;46(8):1105-13.
• [3] Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
• [4] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [5] Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
• [6] Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
• [7] Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
• [8] Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
• [9] Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
• [10] GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
• [11] Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
• [12] Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.
• [13] Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
• [14] How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
• [15] Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
• [16] Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
• [17] Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
• [18] The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
• [19] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [20] Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
• [21] Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
• [22] Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.